Bone metastases in men with prostate cancer may be associated with severe bone pain and the development of skeletal complications. Zoledronic acid (Zometa) has demonstrated a significant reduction in skeletal complications, whereas pamidronate (Aredia) has not. A comparison of these two bisphosphonates on skeletal complications and bone markers at six months shows the superiority of zoledronic acid. Zoledronic acid also appears to provide long-term reductions in skeletal morbidity for men with prostate cancer and bone metastases.
Go to Previous Page
Go to Next Page